Neurology News

The FDA has granted breakthrough therapy designation to Cybin’s CYB003, a proprietary deuterated psilocybin analog in development for treatment of major depressive disorder, according to a company press release.

The CDC published a guide that hospitals can use to reduce the risk for burnout among health care staff.

The FDA has approved Lenmeldy as the first gene therapy to treat children with pre-symptomatic late infantile, pre-symptomatic early juvenile or early symptomatic early juvenile metachromatic leukodystrophy.

WEST PALM BEACH, Fla. — Treatment with evobrutinib was nonsuperior to teriflunomide in confirmed disability progression at 12 and 24 weeks for those with relapsing forms of multiple sclerosis, according to a presenter at ACTRIMS 2024.

Agamree oral suspension 40 mg/mL is now commercially available in the United States for the treatment of Duchenne muscular dystrophy in patients aged 2 years and older, according to a press release.

WEST PALM BEACH, Fla. — The “wearing-off” effect with monoclonal antibodies prescribed for multiple sclerosis led to treatment dissatisfaction and was associated with depression, according to a poster from ACTRIMS 2024.

WEST PALM BEACH, Fla. — In-home video taken by adults with multiple sclerosis is a feasible and valid method to determine the mechanism and motion of their gait, according to a poster from ACTRIMS 2024.

CuraSen Therapeutics has announced positive data from a phase 2a study of its combination adrenergic activator, CST-2032/CST-107, for patients with mild cognitive impairment or mild dementia from Alzheimer’s or Parkinson’s disease.

WEST PALM BEACH, Fla. — Variability and length of pauses in speech may indicate cognitive impairment for German-speaking individuals with multiple sclerosis, according to a poster from ACTRIMS 2024.

A novel chimeric antigen receptor T-cell therapy produced significant tumor reductions in patients with glioblastoma, results from a phase 1 trial published in The New England Journal of Medicine showed.